BioSpace News Archive

Significant Test Manufacturing Capacity, Large Installed Base of Automated Instruments Yield Testing Breakthrough --

Silverback Therapeutics™ (“Silverback”), a biopharmaceutical company advancing a pipeline of therapies that are systemically delivered, but locally active, today announced that preclinical data supporting development of its lead ImmunoTAC™ candidate, SBT6050, has been a

HiFiBiO Therapeutics will take a pioneering approach to clinical development of its pipeline of antibody candidates by using patient stratification biomarkers identified by the company’s proprietary Drug Intelligent Science (DIS™) CAMBRIDGE, Mass. & SHANGHAI & PARIS--( BUSINESS WIRE )-- Scientists at HiFiBiO Therapeutics have generated preclinical data packages for novel monoclonal antibodies that demonstrate favorable clinical development

Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the presentation of new data at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II , taking place f

TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will present an e-poster at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, taking place June 22-24, 2020. The e-poster presentation will highlight preclinical data of the Company’s proprietary T Cell Receptor Fusion Co

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced companywide activities in support of hae day :-) 2020, a global awareness day for hereditary angioedema (HAE). BioCryst stands in solidarity with the HAE community by participating in the annual HAE Global Walk. Since actual community walks cannot currently be organized, BioCryst employees around the world are joining virtually with others supporting hae day :-) b

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the first quarter ended March 31, 2020, and highlighted recent corporate accomplishments.

Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL PBCAR0191 Phase 1/2a Trial is Progressing with Updated Interim Data Expected in 2020; Phase 1/2a Trial of PBCAR269A in Patients with Multiple Myeloma Expected to Begin in 2020 Expect to Select Clinical Candidate for in vivo Gene Correction Program Targeting PH1 in 2020 DURHAM, N.C., May 15, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company de

-Preclinical Data on Lead Immunotherapy Candidate NL-201 Including Immunogencity Results in Non-Human Primates- -Novel Conditional Activation Platform Enabled by De Novo Protein Technology- -Preclinical Results Demonstrate Ability of NL-201 to Expand and Enhance CAR‑T Cell Activity- SEATTLE, May 15, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein thera

– Data builds on positive data presented at American Society of Hematology in December 2019 and EHA-EMBT 2 nd European CAR T Cell Meeting in February 2020 – Conference Call and Webcast to be held Monday, June 15, 2020 at 8:30 am EDT / 1:30 pm BST LONDON, May 15, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced presentations related to its AUTO1 and AUTO3 p